ALK and non-small cell lung carcinoma: performed a network meta-analysis of 25 RCTs comparing the treatments for BMs from EGFR/ALK-negative/unselected NSCLC and found that ICI-based therapies, notably those incorporating ICI combinations, have demonstrated significant potential in managing previously treated BMs stemming from EGFR/ALK-negative or non-specifically selected NSCLC cases (38).